3rd Quarter - Report

TEVA PHARMACEUTICALS USA, INC. for TEVA PHARMACEUTICALS USA INC

Period 3rd Quarter 2009 Filed Oct 20, 2009 Signed by Debra S. Barrett, Sr. VP Gov't Affairs

Official filing
Firm
TEVA PHARMACEUTICALS USA, INC.
Client
TEVA PHARMACEUTICALS USA INC
Income
—
Expenses
$770,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R. 3200, "America's Affordable Health Choices Act" and Senate Finance Committee healthcare reform proposal (provisions relating to pharmaceuticals).

Foreign entity interest: Teva Pharmecutical Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA Inc., has an indirect interest in the issues listed above.

LobbyistCovered position, as disclosed
DEBRA BARRETT —
ROBERT FALB —
DAVID SANDERS —
TERRI STEWART —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Patent & Trademark Office (PTO); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); Commerce, Dept of (DOC)

Bills named: H.R. 3200 (111th)

Pharmacy PHA

S. 301, Physician Payments Sunshine Act of 2009; H.R. 1859 and S. 767, Independent Drug Education and Outreach Act of 2009; H.R. 1427 and S. 726, Promoting Innovation and Access to Life-Saving Medicine Act; H.R. 1548, Pathway for Biosimilars Act; legislative proposals relating to "doughnut hole" impact; and FDA implementation of the Food & Drug Administration Amendments Act ("FDAAA").

Foreign entity interest: Teva Pharmaceutical Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA Inc., has an indirect in the issues listed above.

LobbyistCovered position, as disclosed
DEBRA BARRETT —
ROBERT FALB —
DAVID SANDERS —
TERRI STEWART —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); Patent & Trademark Office (PTO)

Bills named: S. 726 (111th), S. 767 (111th), H.R. 1427 (111th), H.R. 1548 (111th), S. 301 (111th), H.R. 1859 (111th)

Trade (domestic/foreign) TRD

Trade agreements and other trade-related matters relating to intellectual property and pharmaceuticals.

Foreign entity interest: Teva Pharmaceutical Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA Inc., has an interest in the issues listed above.

LobbyistCovered position, as disclosed
DEBRA BARRETT —
DAVID SANDERS —
TERRI STEWART —

Contacted: Patent & Trademark Office (PTO); Commerce, Dept of (DOC); U.S. Trade Representative (USTR); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Copyright/Patent/Trademark CPT

H.R. 1260, S. 515 and S. 610, Patent Reform Act of 2009; H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009; and S. 369, Preserve Access to Affordable Generics Act.

Foreign entity interest: Teva Pharmaceutical Industires, Ltd., as an indirect parent of Teva Pharmaceuticals USA Inc., has an indirect interest in the issues listed above.

LobbyistCovered position, as disclosed
DEBRA BARRETT —
DAVID SANDERS —
TERRI STEWART —

Contacted: Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); SENATE; Patent & Trademark Office (PTO); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES

Bills named: H.R. 1260 (111th), S. 610 (111th), S. 515 (111th), S. 369 (111th), H.R. 1706 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.